

2. Active ingredients – all active ingredients manufactured with this intermediate

Active/Current APIs						
Name	CAS	Originator	Developer	Market Status	Use	Roman Number
A-317491	475205-49-3	Abbott		Reagent	Analgesic	IV
Aciclovir	59277-89-3	Wellcome Foundation (GSK)	Generics	Launched	Antiviral	XIII
Aganepag ethanediol	1192760-33-0	Allergan		Phase 2	Antiglaucoma	XXIII
Amrubicin	110267-81-7 ; 110311-30-3 (hydrochloride salt)	Sumitomo Chemical (Japan)	Sumitomo Dainippon Pharma (Japan) ; Celgene (US)	Launched	Antineoplastic	XXII
AN-1677		Anacor	Anacor	Preclinical	Antifungal	VIII
Anecortave	7753-60-8	Alcon	Alcon	Launched	Antiglaucoma ; Wet Age-related Macular Degeneration (AMD) treatment	V
Apixaban	503612-47-3	Bristol-Myers Squibb (BMS)	Bristol-Myers Squibb (BMS) ; Pfizer	Launched	Anticoagulant ; Antithrombotic	V C4H6O2
Aprocitentan	1103522-45-7	Actelion Pharmaceuticals (Switzerland)	Idorsia Pharmaceuticals (Switzerland) ; Janssen Biotech (US)	Phase 3	Antidiabetic ; Pulmonary Arterial Hypertension (PAH) treatment ; Anti-edema	XVI
Aranidipine	86780-90-7	Maruko Pharmaceutical		Launched	Antihypertensive	I
AS-101	106566-58-9	University of Bar Ilan (Israel)	BioMAS Ltd. (Israel) ; Feramda (Israel) ; Cassiopea (Italy)	Phase 2 ; Orphan Drug Status	Antineoplastic ; Immunomodulator ; Antiviral ; Anti-alopecia ; Antipsoriatic ; Neovascular Age-related Macular Degeneration (AMD) treatment	I
ASM-002		University of Laval		Preclinical	Anti-asthmatic ; Chronic Obstructive Pulmonary Disease (COPD) treatment	IV (CH2OH)2